Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 198

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 11
Chunk 198
---
3 – one counterparty for 40%) of which $nil (2023 - $nil) was past due, considered to be impaired and fully provided for.
 
Generally, the Company does not require collateral or other security from customers for trade accounts receivable; however, credit is extended following an evaluation of creditworthiness. In addition, the Company performs ongoing credit reviews of all of its customers and determines expected credit losses. On this basis, as of December 31, 2024, the Company has provided for all outstanding and unpaid amounts relating to its operations.
 
The maximum exposure to credit risk approximates the amount recognized in the Company’s consolidated statement of financial position.
 

104
---

(b)   Liquidity
         risk  
---------------
 
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages this risk through the management of its capital structure by monitoring rolling forecasts of the Company’s cash and cash equivalents on the basis of expected cash flows.
 
All of the Company’s financial liabilities except lease liabilities are current liabilities with expected settlement dates within one year. The maturity analysis for lease liabilities is disclosed in note 14.
 
While the Company has $16,393 in cash and cash equivalents at December 31, 2024, the Company has noted the existence of a material uncertainty that raises substantial doubt about the Company’s ability to continue as a going concern.

(c)      Foreign   
      exchange risk
-------------------
 
The Company is exposed to foreign exchange risk due to its investments in foreign operations whose functional currency is the Canadian Dollar. A table summarizing the impact of a 10% change in the foreign exchange rates of the Canadian dollar against the US dollar on the financial assets and liabilities of the Company is presented in note 23 to our consolidated financial statements included in this Annual Report on Form 20-F at Item 18.